Join to view full profile
1100 Fairview Ave N# D5-100Seattle, WA 98109
Phone+1 206-618-5181
Fax+1 206-606-1025
Dr. Veatch is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2013 - 2016
University of WashingtonResidency, Internal Medicine, 2010 - 2013
University of Washington School of MedicineClass of 2010
Certifications & Licensure
WA State Medical License 2010 - 2028
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Reprogramming engineered autologous T cells to overcome resistance in patients with Merkel cell carcinoma.Yuta Asano, Joshua R Veatch, Cheng-Jung Sung, Tzu-Hao Tang, Francesco Mazziotta
Science Translational Medicine. 2026-09-09 - Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-g...Anna B Halpern, Megan Othus, Mary-Elizabeth M Percival, Cristina Ghiuzeli, Jacob S Appelbaum
Leukemia. 2026-09-01 - Response of B Cells Specific for Polyomavirus-Derived Oncoprotein Is Predictive of Merkel Cell Carcinoma Tumor Control.Haroldo J Rodriguez Chevez, Allison J Remington, Matthew D Gray, Rian Alam, Macy W Gilmour
Cancer Immunology Research. 2026-05-04
Press Mentions
New Study Shows mRNA Vaccine Enhances Cancer Immunotherapy TreatmentNovember 8th, 2025
Tip Sheet: New Insights on RSV and Malaria, Metastatic Breast Cancer Resources for Patients — and Fred Hutch at ASHDecember 5th, 2024
New Initiative Bolsters Washington State Life SciencesNovember 19th, 2024
Grant Support
- Targeting the tumor microenvironment with engineered CD4+ T cellsFRED HUTCHINSON CANCER CENTER2024–2029
- Therapeutic applications of CD4+ T cells specific for oncogenic driver mutationsFRED HUTCHINSON CANCER CENTER2020–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
